EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are approved for metastatic colorectal cancer (CRC).
• Tumor EGFR expression by immunohistochemistry (IHC) does not reliably predict patient response to anti-EGFR therapy.
• Patients with EGFR-IHC-negative tumors can still benefit from these treatments, indicating a need for better selection criteria.

Purpose of the Study:

• To review studies identifying predictive markers for anti-EGFR monoclonal antibody efficacy in metastatic colorectal cancer.
• To explore potential clinical and biological factors that determine patient outcomes with these targeted therapies.

Main Methods:

• Review of major studies evaluating predictive markers for anti-EGFR therapy in metastatic CRC.
• Analysis of clinical and biological data from retrospective series.

Main Results:

• Current immunohistochemistry (IHC) for EGFR expression lacks correlation with treatment outcomes in metastatic CRC.
• Evidence suggests a subpopulation of CRC patients may be more likely to benefit from anti-EGFR antibodies.
• Several potential predictive markers have shown promising results in retrospective analyses.

Conclusions:

• Tumor EGFR expression by IHC is an unreliable predictor of response to anti-EGFR monoclonal antibodies in metastatic CRC.
• There is a critical need for more reliable predictive factors to guide the selection of patients for these expensive and potentially toxic treatments.
• Further research into clinical and biological markers is essential to optimize the use of anti-EGFR therapies in CRC.